Maha Tageldein
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maha Tageldein has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Adam Shlien
Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, ON, Canada
1 shared publication Anita Villani
Genetics and Genome Biology, The Hospital for Sick Children Research Institute, Toronto, Canada
1 shared publicationBrianne Laverty
Department of Medical Biophysics, University of Toronto, Toronto, Canada
1 shared publication- David Malkin
Division of Hematology/Oncology, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Canada
1 shared publication Derek Wong
Princess Margaret Cancer Center, University Health Network, Toronto, Canada
1 shared publication- Erik Ensminger
Department of Medical Biophysics, University of Toronto
1 shared publication
Latest Publications
- Open Access
- 27 August 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-16
Cell-free DNA from germline TP53 mutation carriers reflect cancer-like fragmentation patterns
Germline pathogenic TP53 variants predispose individuals to a high lifetime risk of developing multiple cancers and are the hallmark feature of Li-Fraumeni syndrome (LFS). Our group has previously shown that LFS patients harbor shorter plasma cell-free DNA fragmentation; independent of cancer status. To understand the functional underpinning of cfDNA fragmentation in LFS, we conducted a fragmentomic analysis of 199 cfDNA samples from 82 TP53 mutation carriers and 30 healthy TP53-wildtype controls. We find that LFS individuals exhibit an increased prevalence of A/T nucleotides at fragment ends, dysregulated nucleosome positioning at p53 binding sites, and loci-specific changes in chromatin accessibility at development-associated transcription factor binding sites and at cancer-associated open chromatin regions. Machine learning classification resulted in robust differentiation between TP53 mutant versus wildtype cfDNA samples (AUC-ROC = 0.710–1.000) and intra-patient longitudinal analysis of ctDNA fragmentation signal enabled early cancer detection. These results suggest that cfDNA fragmentation may be a useful diagnostic tool in LFS patients and provides an important baseline for cancer early detection.
- 27 August 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-16
Open AccessCell-free DNA from germline TP53 mutation carriers reflect cancer-like fragmentation patterns
Germline pathogenic TP53 variants predispose individuals to a high lifetime risk of developing multiple cancers and are the hallmark feature of Li-Fraumeni syndrome (LFS). Our group has previously shown that LFS patients harbor shorter plasma cell-free DNA fragmentation; independent of cancer status. To understand the functional underpinning of cfDNA fragmentation in LFS, we conducted a fragmentomic analysis of 199 cfDNA samples from 82 TP53 mutation carriers and 30 healthy TP53-wildtype controls. We find that LFS individuals exhibit an increased prevalence of A/T nucleotides at fragment ends, dysregulated nucleosome positioning at p53 binding sites, and loci-specific changes in chromatin accessibility at development-associated transcription factor binding sites and at cancer-associated open chromatin regions. Machine learning classification resulted in robust differentiation between TP53 mutant versus wildtype cfDNA samples (AUC-ROC = 0.710–1.000) and intra-patient longitudinal analysis of ctDNA fragmentation signal enabled early cancer detection. These results suggest that cfDNA fragmentation may be a useful diagnostic tool in LFS patients and provides an important baseline for cancer early detection.